Celldex Therapeutics (CLDX) Common Equity (2016 - 2025)
Historic Common Equity for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $598.4 million.
- Celldex Therapeutics' Common Equity fell 2386.32% to $598.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.4 million, marking a year-over-year decrease of 2386.32%. This contributed to the annual value of $747.0 million for FY2024, which is 7405.77% up from last year.
- Per Celldex Therapeutics' latest filing, its Common Equity stood at $598.4 million for Q3 2025, which was down 2386.32% from $655.4 million recorded in Q2 2025.
- Over the past 5 years, Celldex Therapeutics' Common Equity peaked at $838.6 million during Q1 2024, and registered a low of $182.3 million during Q2 2021.
- Its 5-year average for Common Equity is $477.1 million, with a median of $419.5 million in 2021.
- In the last 5 years, Celldex Therapeutics' Common Equity plummeted by 2857.37% in 2023 and then soared by 21854.38% in 2024.
- Over the past 5 years, Celldex Therapeutics' Common Equity (Quarter) stood at $419.5 million in 2021, then dropped by 22.24% to $326.2 million in 2022, then skyrocketed by 31.57% to $429.2 million in 2023, then soared by 74.06% to $747.0 million in 2024, then fell by 19.9% to $598.4 million in 2025.
- Its Common Equity was $598.4 million in Q3 2025, compared to $655.4 million in Q2 2025 and $703.0 million in Q1 2025.